Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

Surge in allied health spending sees Healthia confirm a big boost in earnings guidance

  • In News
  • January 31, 2023
  • Alfred Chan
Surge in allied health spending sees Healthia confirm a big boost in earnings guidance

After two years of lockdowns and pandemic health concerns, the sun is back shining on allied health company Healthia (ASX: HLA) which saw a big upswing in trading in November and December after many had been putting off non-urgent medical appointments during the pandemic. 

The increased trading was witnessed across Healthia’s three disciplines – podiatry, physiotherapy and optometry. Importantly, the Company is no longer witnessing abnormally high staff absenteeism. During the peak of COVID-19 and its subsequent outbreaks, unwell clinicians resulted in cancelled appointments for the clinic. 

In their latest trading update, Healthia expects that its revenue for the six months ended 31 December 2022 (H1) will be approximately $122.5m – $127.5m. On the low end, this would represent a 31.7% increase on the previous corresponding period. 

On the earnings level, underlying EBITDA is expected to be in the range of $17.7m to $18.3m which would be a 45-50% increase on last year. 

The strong uplift in trading has prompted Healthia to reconfirm its FY23 guidance where the Company anticipates more than $40 million in underlying EBITDA. At the lower end, this will represent at least a 63% increase on FY22 when delivering $24.5m. 

“Trading conditions in H1FY23 have shown the business is moving back toward pre-pandemic levels, with impacts from patient cancellations and staff absenteeism subsiding,” said Healthia CEO, Wesley Coote. 

“We are pleased with the expected underlying H1FY23 performance, particularly over key trading months in November and December. Trading to date in January is pleasing and in line with our expectations, with a strong recovery against last year which was impacted by COVID-19. 

“We are proud of the engagement of our team and business and look forward to continuing to deliver on our organic and acquisition growth, via our 4-3-4 strategies, for the remainder of FY2023.”

The 4-3-4 strategy was unveiled by Coote in October 2022 at Healthia’s Inspired 2022 conference which was attended by more than 1,000 allied health professionals from the Healthia network. More specifically, it focuses on Healthia’s 4 key strategies, 3 unique selling propositions and 4 measurable outcomes which were detailed in their recent investor newsletter. 

Increased trading following the Inspired 2022 conference reflected a boost in morale across the Healthia network where many team members met face-to-face for the first time in three years. The event featured allied health experts from around the world sharing research on the latest medical developments in the allied health industry, and industry-leading education that enable clinicians to offer new services at their respective clinics. 

In the months ahead, Healthia expects increased trading to be assisted with their latest graduate intake where 110 allied health professionals enter the Healthia Graduate Program next month. The program has been particularly popular amongst podiatry, physiotherapy and optometry graduates who have a clear pathway towards clinic ownership within Healtha’s network of more than 300 allied health businesses. 

Included in Healthia’s trading update was confirmation that the Company intends to deploy at least $20 million towards clinic acquisitions in FY23. Inbound inquiries are primarily generated by Healthia’s public profile where the Company has proven its marketing, human resources, IT and administrative services drive organic growth in clinics upon integration into the Healthia network. 

Healthia will report its audited Half Year results in February 2023.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
*Owners of this website are shareholders in a company mentioned in this article and have been engaged by them to assist in investor communications
  •  
  •  
  •  
  •  
  • allied health
  • asx hla
  • healthcare
  • healthia
  • HLA
  • Wesley Coote
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.